Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
2018-02-07 |
ArQule (USA - MA) Roivant Sciences (USA) |
derazantinib |
intrahepatic cholangiocarcinoma (iCCA) |
licensing |
Cancer - Oncology - Liver diseases - Hepatic diseases |
Licensing agreement |
2018-02-06 |
InflaRx (Germany) |
member of the board of directors |
|
nomination |
Inflammatory diseases |
Nomination |
2018-02-05 |
Orchard Therapeutics (UK) |
member of the scientific advisory board |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-02-05 |
Oryzon Genomics (Spain) |
member of the scientific advisory board |
|
nomination |
Cancer - Oncology - Neurodegenerative diseases |
Nomination |
2018-01-31 |
Aicuris (Germany) Merck&Co (USA) |
investigational medicines targeting Human Cytomegalovirus (HCMV), including letermovir (AIC246) |
treatment and prevention of HCMV infection in transplant recipients |
licensing - development - commercialisation |
Infectious diseases - Transplantation |
Milestone |
2018-01-31 |
Innate Pharma (France) |
member of the supervisory board |
|
nomination |
Cancer - Oncology |
Nomination |
2018-01-30 |
AB Biosciences (USA - MA) Shire (UK - USA) |
pan receptor interacting molecule (PRIM) program |
|
licensing - development - commercialisation |
Autoimmune diseases |
Licensing agreement |
2018-01-30 |
Innate Pharma (France) MedImmune (USA - global biologics arm of AstraZeneca (UK) |
durvalumab and IPH5401 |
advanced solid tumors |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2018-01-29 |
Ultragenyx Pharmaceutical (USA - CA) |
chief medical officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-01-25 |
Synpromics (UK) UCL Great Ormond Street Institute of Child Health (UK) |
synthetic tissue-specific promoters for use in the specialised cells of the immune system |
pathologies affecting the haematopoietic system |
research - development |
Cancer - Oncology - Immunological diseases |
Development agreement |
2018-01-25 |
Alligator Bioscience (Sweden) Theradex Oncology (USA - NJ) |
ATOR-1015 |
|
services contract |
Cancer - Oncology |
Services contract |
2018-01-24 |
Spark Therapeutics (USA - PA) Novartis (Switzerland) |
Luxturna™ (voretigene neparvovec-rzyl - SPK-RPE65) |
|
licensing |
Rare diseases - Genetic diseases - Ophtalmological diseases |
Licensing agreement |
2018-01-22 |
Sillajen (Republic of Korea) ABL Europe (France) |
Pexa-Vec (formerly JX-594), JX-970 |
|
production - manufacturing |
Technology - Services - Cancer - Oncology |
Production agreement |
2018-01-22 |
Iontas (UK) Sanofi (France) |
antibodies using Iontas’ proprietary Mammalian Display Technology |
|
collaboration |
Technology - Services |
Collaboration agreement |
2018-01-18 |
Gilead Sciences (USA - CA) Pfizer (USA - NY) |
Yescarta™ (axicabtagene ciloleucel) and utomilumab large B-cell lymphoma |
refractory large B-cell lymphoma |
clinical research |
Cancer - Oncology |
Clinical research agreement |
2018-01-18 |
Alligator Bioscience (Sweden) |
vice president business development |
|
nomination |
Cancer - Oncology |
Nomination |
2018-01-17 |
Homology Medicines (USA - MA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-01-17 |
Synpromics (UK) |
vice-president |
|
nomination |
Technology - Services |
Nomination |
2018-01-17 |
Orchard Therapeutics (UK) |
chief financial officer and chief business officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
2018-01-17 |
Glythera (UK) |
chief scientific officer (CSO) |
|
nomination |
Cancer - Oncology |
Nomination |